Leerink Partners Cuts NeuroPace to Market Perform From Outperform
Leerink Partners cut its rating on NeuroPace to Market Perform from Outperform and announced a $7.00-per-share price target.
Leerink Partners cut its rating on NeuroPace to Market Perform from Outperform and announced a $7.00-per-share price target.